March 9th, 2013
ACC.13 Headquarters
CardioExchange Editors, Staff
CardioExchange is dedicated to bringing you the latest from ACC.13. Check out our coverage below ─ and some of the great debates these posts have sparked ─ then tell us what you think!
News:
- Following an Embargo Break PREVAIL Trial Won’t be Presented at ACC
- HPS2-THRIVE: A ‘Disappointing But Clear’ Result
- Cangrelor During PCI May Reduce Ischemic Events
- Fibrinolysis May Benefit Late-Arriving STEMI Patients
- Eplerenone May Prevent Heart Failure in Acute STEMI Patients
- Another Negative Trial of Darbepoetin Alfa
- Was Atherosclerosis the Real Curse of the Mummy?
- Two Trials Explore On-Pump Versus Off-Pump Bypass Surgery
Analysis:
Follow our Fellows:
- The Real World Intrudes on the Start of the Meeting
- A Fellow Reflects on the Program and on her Progress from Observer to Educator
- Data Sources for Young Investigators
- New Approaches to LDL Lowering
- Great Venue, Great Sessions, but Disappointments Too
- Thinking About What Comes After Fellowship
- The Real Question About Reducing Hospital Readmissions
- You Are My Sunshine
- Learning to Network
NEJM — Recent Cardiology Articles- The Broader Dangers of Abandoning SGM Health Research August 15, 2026When research is defunded not for scientific reasons but because it has become politically inconvenient, the ensuing damage is wide ranging, affecting far more than the disfavored topics and populations.
- In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia August 13, 2026The authors report reductions in PCSK9 and LDL cholesterol levels and no dose-limiting toxic effects in persons with hypercholesterolemia treated with VERVE-102, a base editor targeting PCSK9.
- A New Approach to Lowering LDL Cholesterol August 13, 2026The pioneering work of Vafai and colleagues, reported in this issue of the Journal,1 paves the way for a new type of low-density lipoprotein (LDL) cholesterol–lowering therapy called VERVE-102: a therapy that appears to lower LDL cholesterol levels enough to reduce the risk of atherosclerotic cardiovascular...
- Last Man Running August 13, 2026As the health of his brother and running buddy rapidly declines and he faces his own health scares, a physician feels compelled — and grateful — to keep moving forward.
- Mineralocorticoid Receptor Antagonism — FINDing Another Benefit August 6, 2026Aldosterone plays a critical role in the homeostasis of blood pressure and volume by engaging mineralocorticoid receptors in the kidneys, heart, and other organs.1 However, overactivation of mineralocorticoid receptors contributes to the pathogenesis of chronic kidney disease (CKD) and heart failure, in part by causing inflammation and fibrosis....
- The Broader Dangers of Abandoning SGM Health Research August 15, 2026